Lanvis (Tioguanine)

Tioguanine is converted inside cells to thioguanine nucleotides, which become incorporated into DNA and RNA. This fraudulent incorporation interferes with nucleic‑acid synthesis, leading to reduced replication of rapidly dividing cells, especially malignant lymphoid or myeloid cells, and produces an overall immunosuppressive effect.

The dose of Lanvis is individualized by the treating physician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Only a qualified prescriber can determine the appropriate dosing schedule and any necessary adjustments.

Safety data for tioguanine in pregnancy and lactation are limited. The drug may cross the placenta and be excreted in breast milk, potentially affecting the fetus or infant. Use only if the potential benefit justifies the potential risk, and discuss alternatives with a healthcare professional.

To place an order, submit an enquiry on the Lanvis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both tioguanine (Lanvis) and azathioprine belong to the thiopurine class and share a similar mechanism of incorporating fraudulent nucleotides into DNA/RNA. Tioguanine is often used when azathioprine is ineffective or not tolerated, but both require careful monitoring for bone‑marrow suppression and liver toxicity. Choice depends on clinical response, tolerability and physician preference.

Lanvis should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and humidity, and ensure the container is tightly closed when not in use.

Lanvis is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency depend on the individual treatment plan, and patients should follow the dosing instructions provided by their healthcare professional.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, life‑threatening infections due to immunosuppression, hepatic toxicity, pancreatitis, and rare but severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, abnormal blood counts, or liver dysfunction.

Lanvis is contraindicated in patients with known hypersensitivity to tioguanine or other thiopurines, in those with severe hepatic impairment, and in individuals with active, uncontrolled infections. Caution is also advised for patients with significant renal dysfunction, pregnant or breastfeeding women, and anyone taking interacting medications without appropriate monitoring.